Premium
Cardiovascular Effects of H 2 ‐receptor Antagonists
Author(s) -
Hughes David G.,
Dowling Elizabeth Anne,
DeMeersman Ronald E.,
Garnett William R.,
Karnes H. Thomas
Publication year - 1989
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1989.tb03365.x
Subject(s) - pharmacology , medicine , chemistry , cardiology
The type II histamine receptor antagonists, cimetidine and ranitidine, widely used in treatment of peptic ulcer disease have been reported to cause bradycardia. To evaluate the cardiovascular effects of H 2 antagonists nineteen healthy volunteers were entered into a double‐blind crossover comparison of cimetidine 300 mg qid, ranitidine 150 mg bid, and placebo. Subjects ingested study medicine for 7 days prior to being tested by the Bruce Exercise Test Heart rate, blood pressure, oxygen consumption, expiratory volume, and fractional expiration of CO 2 and O 2 were measured at rest, exercise and recovery. A plasma sample for determination of cimetidine and ranitidine levels were obtained prior to the exercise period. Multivariate analysis and paired t test revealed no significant differences for the cardiovascular or pulmonary variables. However, in 5 subjects, the heart rate at 25% maximum VO2 was depressed 8% ( P ≤ 0.03). This effect in a small percentage of the population suggests that further studies are needed to determine if subpopulations are affected .